Drug Profile


Alternative Names: E4/DRSP; Estelle; Estetrol/Drospirenone

Latest Information Update: 26 Nov 2016

Price : $50

At a glance

  • Originator Estetra S.A.
  • Class Androstenes; Antiandrogens; Gonadal steroid hormones; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor beta modulators; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Contraception

Most Recent Events

  • 01 Sep 2016 Phase-II clinical trials in Contraception (In volunteers) in Netherlands (PO) (NCT02957630)
  • 01 Aug 2016 Phase-III clinical trials in Contraception in USA (PO) (NCT02817841)
  • 01 May 2016 Phase-I clinical trials in Contraception (In volunteers, In adults) in Netherlands (PO) (NCT02874248)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top